David N. Gill, Director at MELINTA THERAPEUTICS, INC. /NEW/ (MLNT), bought 5,000 shares at $6.09 ($30K) on 2018-05-25, disclosed to the SEC on 2018-05-30.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| YMAB | SELL | 2021-01-20 | $93K | — | Filing → |
| YMAB | SELL | 2020-11-20 | $92K | — | Filing → |
| YMAB | SELL | 2020-11-05 | $180K | — | Filing → |